← Evidence map

ReviewCureus2026

Emerging Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Evidence, Clinical Utility, and Future Perspectives.

Sushant S Dhanavade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Emerging Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Evidence, Clinical Utility, and Future Perspectives. | OpenQuestion